Bioventus (BVS) Accumulated Expenses (2020 - 2026)

Bioventus (BVS) has reported Accumulated Expenses for 7 consecutive years, with $109.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses fell 3.79% year-over-year to $109.4 million; the trailing twelve-month figure through Jun 2026 stood at $109.4 million (down 3.79% YoY), and the FY2025 full-year result was $130.2 million, down 4.15% from the prior year.
• Accumulated Expenses rose to $109.4 million in Q2 2026 per BVS's latest filing, from $101.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $146.8 million in Q3 2022 and bottomed at $101.1 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $120.6 million across 5 years, with a median of $119.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 39.44% in 2022, then decreased 18.8% in 2025.
• Over 5 years, Accumulated Expenses stood at $111.6 million in 2022, then grew by 7.37% to $119.8 million in 2023, then climbed by 13.43% to $135.9 million in 2024, then retreated by 4.15% to $130.2 million in 2025, then slipped by 16.03% to $109.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $109.4 million, $101.1 million, and $130.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.